Clinical Trial: Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy

Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title:

Brief Summary:

The Leber Hereditary Optic Neuropathy is a genetic disorder caused by maternal transmission of mitochondrial DesoxiroboNucleid Acid mutations. It is manifested by a rapidly progressive blindness, profound, due to atrophic optic nerve. The visual loss is primarily unilateral bilateralisation taking place in the vast majority of cases in weeks or months. The neuro-cardio-protective properties of cyclosporine (and its analogs specifically targeting the anti-apoptotic mechanisms) are particularly promising.

The investigators hypothesis is that cyclosporine may limit apoptosis during the acute phase of the disease process and would limit the loss of visual acuity and improve the visual prognosis of these patients.

Detailed Summary:
Sponsor: University Hospital, Angers

Current Primary Outcome: Measurement of visual acuity with Monoyer, Early Treatment Diabetic Retinopathy Study and Parinaud scales [ Time Frame: at 9 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Angers

Dates:
Date Received: June 25, 2014
Date Started: July 2011
Date Completion:
Last Updated: June 26, 2014
Last Verified: January 2014